Stock of the week – CSL

Portfolio Manager, Tribeca Investment Partners
Print This Post A A A

What is the stock?

CSL is Australia’s leading biotechnology company. It is the global leader in the blood plasma therapies sector and the second-largest supplier of seasonal influenza vaccines, with combined annual sales of more than US$7.5 billion.

How long have you held the stock?

Take a free trial to continue reading

Already have an account? Login to continue reading.

By proceeding you understand and agree to the site's terms and conditions

Also from this edition